REG - Hikma Pharmaceutical - Notice of Results <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

10/08/2016 09:25

RNS Number : 7859G
Hikma Pharmaceuticals Plc
10 August 2016
Notice of Results
LONDON, UK, 10 August, 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+ S&P, both stable), the fast growing pharmaceuticals company, will announce its interim financial results for the six months ended 30 June 2016 on Wednesday 24 August 2016. 
A presentation and webcast for analysts will be held at 9.30am BST at FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. 
To join via conference call please dial: +44 (0) 20 3003 2666
UK Toll Free Number: 0808 109 0700
The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://cache.merchantcantos.com/webcast/webcaster/4000/7464/16532/63539/Lobby/default.htm 
Playback facility:
A playback of the conference call will be available up to 7 days after the presentation.
UK & International Number: +44 (0) 20 8196 1998
UK Toll-Free Number: 0800 633 8453
Replay PIN code: 8050955#
-Ends-
Enquiries
Hikma Pharmaceuticals PLC 

Susan Ringdal, VP Corporate Strategy and Investor Relations
+44 (0)20 7399 2760/+44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations
+44 (0)20 7399 2765/+44 7818 060211
Zeena Murad, Investor Relations Manager
+44 (0)20 7399 2768/+44 7771 665277


FTI Consulting

Ben Atwell/Matthew Cole
+44 (0)20 3727 1000
About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa (MENA) and Europe. In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NORZMGMRRGGGVZG